Last reviewed · How we verify
I-131-CLR1404
At a glance
| Generic name | I-131-CLR1404 |
|---|---|
| Also known as | 18-(p-[I-131]-iodophenyl)octadecyl phosphocholine, CLR1404, 1404, 131I-CLR1404, CLR 131 |
| Sponsor | Cellectar Biosciences, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom (PHASE2)
- Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG (PHASE1)
- Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas (PHASE1)
- Phase 1 Study of CLR 125 in Triple Negative Breast Cancer (PHASE1)
- CLR 131 Combined With Radiation for Head and Neck Cancer (PHASE1)
- Dose Escalation Study of I-131-CLR1404 in Patients With Relapsed or Refractory Multiple Myeloma (PHASE1)
- Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma (PHASE2)
- Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- I-131-CLR1404 CI brief — competitive landscape report
- I-131-CLR1404 updates RSS · CI watch RSS
- Cellectar Biosciences, Inc. portfolio CI